Price to book forward of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT
This article displays the "Price to book forward" metric for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) on the TradingView platform. It provides financial data and indicates that the market was closed at the time the information was presented. The content primarily lists navigation and platform features, with the key data point being the stock's price to book forward value.
Price to sales forward of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT
This article briefly mentions the "Price to sales forward" metric for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT). It appears to be a financial data point from TradingView, indicating a value change for the company. The rest of the content consists of navigation links and copyright information for the TradingView platform and its data providers.
PHAT - Phathom Pharmaceuticals Inc Revenue Breakdown
This article provides a detailed financial breakdown for Phathom Pharmaceuticals Inc (PHAT), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, stock ownership details, and price performance over different periods. The data offers an overview of the company's financial health and stock market activity.
Discipline and Rules-Based Execution in PHAT Response
This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), noting conflicting sentiment and a mid-channel oscillation pattern. It highlights an exceptional risk-reward setup targeting a 29.0% gain against a 0.3% risk, with specific entry, target, and stop-loss points for position, momentum breakout, and risk hedging strategies. The analysis is based on AI models and multi-timeframe signal analysis, providing support and resistance levels across different time horizons.
Phathom Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PHAT)
This article provides financial data and analyst estimates for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT). It covers details like current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports. The content also addresses frequently asked questions regarding PHAT's stock performance and investment outlook.
PHAT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Phathom Pharmaceuticals, Inc. (PHAT) stock, including analyst price targets and future predictions for 2027. It details the company's recent stock performance, financial metrics like revenue and earnings, and upcoming events such as the next earnings report. The piece also addresses frequently asked questions about PHAT's stock price, volatility, market capitalization, and dividend policy.
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating
Craig-Hallum has reiterated its Buy rating on Phathom Pharmaceuticals (PHAT.US). This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study
Phathom Pharmaceuticals has announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets for the treatment of eosinophilic esophagitis (EoE) in adults. The study enrolled 95 patients across 41 sites in the U.S., with topline results expected in the fourth quarter of 2026. The company also recently reported first-quarter 2026 earnings that exceeded EPS expectations, though revenue slightly underperformed.
Phathom Pharmaceuticals completes enrollment in Phase 2 EoE study By Investing.com
Phathom Pharmaceuticals, Inc. has announced the completion of enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets for the treatment of eosinophilic esophagitis (EoE) in adults. The trial enrolled 95 patients and topline results are anticipated in the fourth quarter of 2026. If positive, these results could lead to discussions with the FDA regarding future development and potential regulatory exclusivity extension.
Phathom (PHAT) fully enrolls Phase 2 VOQUEZNA EoE trial, data in Q4 2026
Phathom Pharmaceuticals has completed enrollment for its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) for adults with eosinophilic esophagitis (EoE), enrolling 95 patients across 41 U.S. sites. Topline results are anticipated in the fourth quarter of 2026. Positive outcomes could lead to discussions with the FDA about future development, including a pediatric program that might extend VOQUEZNA’s regulatory exclusivity.
Phathom enrolls 95 adults in VOQUEZNA EoE trial; results due in Q4
Phathom Pharmaceuticals has completed patient enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 study for VOQUEZNA as a treatment for eosinophilic esophagitis (EoE), enrolling 95 adult patients across 41 U.S. sites. Topline results for the 12-week double-blind portion of the trial are anticipated in the fourth quarter of 2026. This study represents the first large, placebo-controlled trial of an acid suppression therapy for EoE, aiming to evaluate if vonoprazan can offer a new oral, non-steroidal treatment option for patients.
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Phathom Pharmaceuticals has completed patient enrollment ahead of schedule for its Phase 2 pHalcon-EoE-201 clinical trial, evaluating VOQUEZNA® (vonoprazan) as a treatment for eosinophilic esophagitis (EoE) in adults. The study, which enrolled 95 patients, is the first large, placebo-controlled trial of an acid suppression treatment for EoE. Topline results are expected in the fourth quarter of 2026, and if positive, could inform future development plans for VOQUEZNA in this growing indication.
Phathom completes enrollment in vonoprazan trial for EoE
Phathom Pharmaceuticals Inc. announced the completion of enrollment for its Phase 2 clinical trial evaluating vonoprazan tablets for eosinophilic esophagitis (EoE), involving 95 adult patients across 41 U.S. sites. Topline results are expected in Q4 2026. The company, which has seen 150% revenue growth in the past year and boasts an 85% gross profit margin, views this as a significant step towards potential FDA approval for EoE, building on its existing approvals for other gastric acid-related conditions.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): When Will It Breakeven?
This article analyzes Phathom Pharmaceuticals, Inc.'s path to profitability, focusing on analyst expectations for when the company will reach breakeven. It reviews the pharmaceutical company's financial performance, including its cash burn rates and anticipated revenue growth, to project its breakeven timeline. The analysis also considers the challenges and opportunities Phathom Pharmaceuticals faces in achieving financial stability.
Phathom Pharmaceuticals Inc (PHAT) Valuation: PE, PB & Fair Value Analysis
Phathom Pharmaceuticals Inc (PHAT) currently has a valuation score of 8.43, placing it 94th out of 157 in the Pharmaceuticals industry. The article notes that relevant data for P/E, P/B, P/S, and P/CF ratios have not been disclosed by the company yet, suggesting a lack of comprehensive financial transparency.
Phathom Pharmaceuticals Inc (PHAT) Financial Health: Profitability & Balance Sheet Analysis
Phathom Pharmaceuticals Inc (PHAT) has a stable financial score of 8.16, ranking 74th in the Pharmaceuticals industry, indicating high operating efficiency. The company reported a significant year-over-year revenue increase of 104.43% to $58.30 million and a net profit increase of 67.80%. While specific financial data for various categories like cash flow and assets have not been fully disclosed, the company shows strong growth potential.
H.C. Wainwright reiterates Buy on Phathom stock, $26 target
H.C. Wainwright has reiterated a Buy rating for Phathom Pharmaceuticals (NASDAQ:PHAT) with a $26 price target, citing substantial upside from its current $10.43 stock price. The firm's positive outlook follows a webinar highlighting clinical enthusiasm for Phathom's drug VOQUEZNA, which also demonstrated strong commercial momentum with 150% revenue growth over the last year. Despite a slight revenue miss, Phathom's recent Q1 2026 earnings beat EPS expectations, reinforcing analyst confidence in the company's financial health and strategic direction.
Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on dividends and stock splits for Phathom Pharmaceuticals Inc (PHAT). It notes that PHAT has not distributed any dividends over the past five years and shows no record of stock splits. The company's current stock performance and market capitalization are also briefly mentioned.
Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Phathom Pharmaceuticals Inc (PHAT), outlining major shareholders, institutional holdings, and related ETF investments. Key shareholders include Frazier Life Sciences Management, L.P. and Medicxi Ventures (UK) LLP, with significant institutional ownership reported for various quarters. The report also categorizes shareholders by type, such as Investment Advisor and Venture Capital firms.
PHAT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $26
HC Wainwright & Co. has reiterated a "Buy" rating for Phathom Pharmaceuticals (PHAT), maintaining its price target at $26. Despite this positive analyst sentiment, the company's GF Score™ is 27/100, reflecting low financial strength and profitability, though it shows positive momentum. The stock is currently trading significantly below the target price, suggesting potential undervaluation.
PHAT - Phathom Pharmaceuticals Inc Stock Price and Quote
This article provides comprehensive stock information for Phathom Pharmaceuticals Inc (PHAT), including its current price, market capitalization, financial metrics, and recent news. It also lists analyst ratings and insider trading activities, offering a detailed overview of the company's financial health and market sentiment.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): When Will It Breakeven?
This article analyzes Phathom Pharmaceuticals' path to profitability, focusing on analyst expectations for revenue growth and projected breakeven points. It highlights the consensus forecast for the company to achieve positive free cash flow by 2026 and provides a financial overview including anticipated earnings and revenue.
Phathom Pharmaceuticals shows negative capital efficiency, destroying value amid high R&D costs.
Phathom Pharmaceuticals currently exhibits a negative Return on Invested Capital (ROIC) of -53.45%, significantly below its Weighted Average Cost of Capital (WACC) of 15.49%, indicating it is destroying shareholder value. This is typical for clinical-stage biopharmaceutical companies due to substantial research and development expenses before commercialization. Compared to its peers, only Arcutis Biotherapeutics shows a positive ROIC, albeit still below its WACC, suggesting better, yet still insufficient, capital efficiency.
[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity
Phathom Pharmaceuticals director Asit Parikh reported gifting 56,000 shares of common stock on May 22, 2026. These transfers were bona fide gifts to a trust benefiting his spouse and were not market trades. The transactions reflect estate or family planning rather than buying or selling activity, with no consideration received.
How (PHAT) Movements Inform Risk Allocation Models
This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) using AI models, highlighting weak near-term sentiment but potential long-term strength. It outlines various trading strategies—position, momentum, and risk hedging—and provides multi-timeframe signal analysis with specific support and resistance levels. The analysis aims to inform risk allocation models by detailing entry/exit points, targets, and stop-loss levels for different risk profiles.
PHAT SEC Filings - Phathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Phathom Pharmaceuticals (PHAT) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, and 8-K material event disclosures. It details recent insider transactions, changes in beneficial ownership by various investment groups like Carlyle and Millennium, and significant executive compensation awards. The resource aims to offer investors and traders access to critical regulatory documents and AI-generated analyses of these filings.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals, Inc. announced that its management team will attend three upcoming investor conferences in May and June: the Craig-Hallum 23rd Annual Institutional Investor Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Management will participate in one-on-one meetings at each event, with fireside chats scheduled for the Jefferies and Goldman Sachs conferences. Investors can access live webcasts and archived recordings on the company's website.
Hear Phathom at three upcoming healthcare investor conferences
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation in three investor conferences in May and June 2026: the Craig-Hallum Institutional Investor Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs Global Healthcare Conference. Management will attend these events to participate in one-on-one meetings and fireside chats. The company, focused on GI treatments, will discuss vonoprazan, its first-in-class potassium-competitive acid blocker.
Phathom (NASDAQ: PHAT) director gains shares via options and RSUs
Phathom Pharmaceuticals director Asit Parikh increased his holdings by exercising options for 17,500 shares at $4.95 each and receiving 24,122 Restricted Stock Units (RSUs). These RSUs will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on his continued board service. Following these transactions, Parikh directly holds 52,122 shares and indirectly holds 120,500 shares through a trust.
Phathom Pharmaceuticals (NASDAQ: PHAT) reports 2026 annual meeting vote outcomes
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) announced the voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders elected three Class I directors for three-year terms, ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026, and gave advisory approval for the compensation of named executive officers. All proposals presented were approved by the stockholders.
Director at Phathom Pharmaceuticals (PHAT) granted 24,122 RSUs
Heidi Fields, a director at Phathom Pharmaceuticals (PHAT), received a grant of 24,122 Restricted Stock Units (RSUs) on May 19, 2026, as part of the company's Non-Employee Director Compensation Program. These RSUs, which have a grant price of $0.00 per share, will vest fully on the earlier of the first anniversary of the grant date or the next annual shareholder meeting, contingent on her continued board service. Following this award, Fields now beneficially holds 54,122 shares of Phathom Pharmaceuticals common stock, reflecting equity compensation rather than a stock purchase.
Director Frank Karbe receives 24,122 RSUs at Phathom (NASDAQ: PHAT) under board compensation plan
Phathom Pharmaceuticals director Frank Karbe was granted 24,122 Restricted Stock Units (RSUs) on May 19, 2026, as part of the company's Non-Employee Director Compensation Program. These RSUs, which convert into common stock upon vesting, are set to vest 100% on the earlier of one year from the grant date or the next annual stockholder meeting, contingent on his continued board service. Following this award, Karbe now directly holds 91,622 shares of Phathom common stock.
Director Michael Cola (PHAT) receives 24,122 RSUs in equity award grant
Michael F. Cola, a director at Phathom Pharmaceuticals (PHAT), was granted 24,122 Restricted Stock Units (RSUs) as an equity award under the company’s Non-Employee Director Compensation Program. These RSUs are not an open-market purchase and will vest 100% on the earlier of one year from the May 19, 2026 grant date or the next annual stockholder meeting, provided Cola remains on the board. This grant increases his direct reported holdings to 63,920 shares.
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom Pharmaceuticals showcased extensive independent research on vonoprazan, the active ingredient in VOQUEZNA, at Digestive Disease Week (DDW) 2026. The meeting featured 31 vonoprazan-related clinical abstracts, including 28 independent analyses covering various gastrointestinal conditions such as GERD, H. pylori eradication, long-term safety, and post-endoscopic submucosal dissection use. A Phathom-sponsored analysis of heartburn and regurgitation from the Phase 3 pHalcon-NERD-301 trial also received a "Poster of Distinction" designation at the event.
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
Needham analyst Joseph Stringer has reiterated a Buy rating for Phathom Pharmaceuticals (PHAT.US) and maintained a target price of $28. According to TipRanks data, Stringer has a 46.5% success rate and a 23.8% average return over the past year. This rating is based on an independent third-party analysis of financial analysts' recommendations.
Number of shareholders of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT
This article provides details on the number of shareholders for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), offering insights into its financial data and market performance. It includes a basic overview of Phathom Pharmaceuticals on the Nasdaq Stock Market. The content appears to be a stub or a data-driven report from TradingView, focusing on shareholder numbers as a key metric.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Phathom Pharmaceuticals (NASDAQ:PHAT) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $25.00. Institutional investors hold a significant 99.01% of the shares, with several major funds increasing their stakes. The company recently reported better-than-expected quarterly earnings and revenue that was largely in line with estimates, though its shares were down slightly to $12.16.
Phathom Pharmaceuticals (Nasdaq:PHAT) - Stock Analysis
Phathom Pharmaceuticals (PHAT) is a biopharmaceutical company focused on gastrointestinal disease treatments, with its stock currently trading significantly below its estimated fair value. Analysts forecast strong earnings growth and anticipate the company reaching profitability in 2026. Recent updates highlight FDA approvals for VOQUEZNA in various GERD conditions, along with ongoing clinical trials and strategic financial management to support its long-term market position.
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline
Phathom Pharmaceuticals (PHAT) saw an 11.0% stock increase after reporting a significantly narrowed Q1 2026 net loss of US$30.37 million, down from US$94.32 million year-over-year. The company reaffirmed its 2026 guidance, expecting net revenues between US$320 million and US$345 million, and targeting operating profitability by Q3 and for the full year, excluding stock-based compensation. This progress supports the investment narrative around its product VOQUEZNA, aiming for sustained profitability despite inherent risks tied to a single product.
Phathom Pharmaceuticals (NasdaqGS:PHAT) Stock Forecast & Analyst Predictions
Phathom Pharmaceuticals (NasdaqGS:PHAT) is projected to experience significant growth, with earnings forecast to increase by 57.5% and revenue by 28.4% annually. The company is expected to achieve profitability in 2027, with numerous analyst updates and price target revisions reflecting both optimism for its product VOQUEZNA and concerns regarding financial risks like shareholder dilution and cash runway. Recent developments include FDA approvals, ongoing clinical trials, and strategic management appointments.
Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3
Phathom Pharmaceuticals has provided a financial outlook for 2026, projecting revenues between $320 million and $345 million. The company aims to achieve operating profitability by the third quarter of 2026. This outlook reflects the company's strategic goals and anticipated growth in the coming years.
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing
Phathom Pharmaceuticals Inc. (PHAT) shows a weak near and mid-term sentiment, but a strong long-term outlook with an exceptional 114.0:1 risk-reward setup. AI models have generated three trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, targeting different risk profiles and holding periods. The analysis highlights key support and resistance levels across various time horizons for PHAT.
147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc.
Hussman Strategic Advisors Inc. recently purchased 147,000 shares of Phathom Pharmaceuticals (NASDAQ:PHAT) valued at approximately $2.44 million, increasing its stake to 0.21%. This comes as Phathom Pharmaceuticals reported Q1 revenue that beat estimates due to strong VOQUEZNA sales, although the company remains unprofitable with a slight EPS miss. Analysts are largely bullish, with a "Moderate Buy" consensus and a $25 price target, and shares rose 7.2% on the news.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX)
This article examines analyst sentiments for three healthcare companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA), and Nanobiotix (NBTX). Phathom Pharmaceuticals received a Strong Buy consensus with significant upside potential, while TELA Bio also garnered a Strong Buy rating. Nanobiotix, however, has a Strong Buy consensus but with a more modest upside, and one analyst maintained a Hold rating.
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call
Phathom Pharmaceuticals reported robust Q1 2026 results, with net revenues doubling year-over-year fueled by strong VOQUEZNA prescription growth and expanded sales force initiatives. Despite short-term revenue being slightly below internal expectations due to seasonality and market access, the company maintained its full-year guidance, emphasizing disciplined spending, a solid cash position, and advancements in its clinical pipeline. Management expects to reach operating profitability later this year, although high gross-to-net discounts and future competition remain potential challenges.
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5% - Should You Buy?
Phathom Pharmaceuticals (NASDAQ:PHAT) saw its stock price rise 7.5% during mid-day trading on Friday, driven by a Q1 revenue beat and narrowed losses for its VOQUEZNA product. Analyst sentiment remains largely positive, with several firms raising price targets and a consensus rating of "Moderate Buy" with a $22.50 target. Despite a slight EPS miss, the improved commercial traction and ongoing analyst support suggest a potentially positive outlook for the company.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals reported its Q1 2026 earnings, showcasing a 104% year-over-year revenue growth to $58.3 million, though missing EPS expectations at $-0.37. The company emphasizes its refined strategy focusing on gastroenterologists for VOQUEZNA, aiming for $1 billion in annual revenue in GI and anticipating a future expansion into primary care. Despite competitive landscape considerations, Phathom maintains its full-year 2026 revenue guidance and expects to achieve operating profitability by Q3 2026, driven by strong new-to-brand prescription rates and disciplined expense management.
GERD drug VOQUEZNA gets 3 posters and a May 4 presentation at DDW
Phathom Pharmaceuticals will highlight its GERD drug VOQUEZNA at Digestive Disease Week (DDW) 2026 with three poster presentations and a product theater session on May 4. The company aims to engage with the GI community and share clinical, patient-reported, and real-world data for VOQUEZNA. This engagement is part of Phathom's ongoing commercialization push for the drug, following recent financial updates emphasizing revenue growth and profitability targets.
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
Phathom Pharmaceuticals will participate in the Digestive Disease Week (DDW) 2026 annual meeting from May 2-5 in Chicago, Illinois. The company plans to highlight its drug VOQUEZNA (vonoprazan) through a product theater presentation and an exhibit booth. Phathom will also present clinical and real-world data across three poster presentations, demonstrating its commitment to advancing GERD treatment.
Phathom Pharmaceuticals (PHAT) Loss Compression Challenges Bearish Narratives After Q1 2026 Results
Phathom Pharmaceuticals (PHAT) released its Q1 2026 results, reporting $57.6 million in revenue and a significant reduction in EPS loss to $0.29. The company's net losses have shrunk from $94.3 million to $21.1 million over six quarters, supporting a bullish outlook on its path to profitability within three years. Despite ongoing trailing losses and negative shareholders' equity, analysts maintain a high fair value and price target, fueled by strong revenue growth forecasts and expected margin improvements.
